Patents by Inventor Philipp Janser
Philipp Janser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251067Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: ApplicationFiled: January 13, 2022Publication date: August 11, 2022Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
-
Patent number: 11254653Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: GrantFiled: May 15, 2020Date of Patent: February 22, 2022Assignee: Novartis AGInventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
-
Patent number: 11208399Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: GrantFiled: May 15, 2020Date of Patent: December 28, 2021Assignee: Novartis AGInventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
-
Publication number: 20210308140Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of disease and disorders mediated by NLRP3.Type: ApplicationFiled: July 23, 2019Publication date: October 7, 2021Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nikolaus Johannes STIEFL, Juraj VELCICKY
-
Publication number: 20200361898Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: ApplicationFiled: May 15, 2020Publication date: November 19, 2020Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
-
Publication number: 20200361899Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.Type: ApplicationFiled: May 15, 2020Publication date: November 19, 2020Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
-
Patent number: 8791100Abstract: The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: GrantFiled: January 28, 2011Date of Patent: July 29, 2014Assignee: Novartis AGInventors: Daniela Angst, Birgit Bollbuck, Philipp Janser, Jean Quancard, Nikolaus Johannes Stiefl
-
Patent number: 8354431Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: (I) wherein the variants R and X are defined in the specification.Type: GrantFiled: February 18, 2008Date of Patent: January 15, 2013Assignee: Novartis AGInventors: Rene Hersperger, Philipp Janser, Wolfgang Miltz
-
Patent number: 8183366Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the variants R, R9, Z, X, Q and Y are defined in the specification.Type: GrantFiled: September 20, 2010Date of Patent: May 22, 2012Assignee: Novartis AGInventors: Rene Hersperger, Philipp Janser, Emil Pfenninger, Hans J Wuethrich, Wolfgang Miltz
-
Publication number: 20110190258Abstract: The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 28, 2011Publication date: August 4, 2011Applicant: NOVARTIS AGInventors: Daniela ANGST, Birgit BOLLBUCK, Philipp JANSER, Jean QUANCARD, Nikolaus Johannes STIEFL
-
Publication number: 20110015180Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the variants R, R9, Z, X, Q and Y are defined in the specification.Type: ApplicationFiled: September 20, 2010Publication date: January 20, 2011Inventors: René Hersperger, Philipp Janser, Emil Pfenninger, Hans Juerg Wuethrich, Wolfgang Miltz
-
Patent number: 7858781Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.Type: GrantFiled: February 10, 2005Date of Patent: December 28, 2010Assignee: Novartis AGInventors: René Hersperger, Philipp Janser, Emil Pfenninger, Hans Juerg Wuethrich, Wolfgang Miltz
-
Publication number: 20100168079Abstract: The present invention relates to biaryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: ApplicationFiled: December 21, 2009Publication date: July 1, 2010Inventors: Daniela Angst, Birgit Bollbuck, Philipp Janser, Jean Quancard
-
Publication number: 20100029609Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R5, R10 and X1-X7 are as defined in the specification.Type: ApplicationFiled: September 6, 2007Publication date: February 4, 2010Inventors: Frederic Berst, Philipp Grosche, Philipp Janser, Frederic Zecri, Birgit Bollbuck
-
Publication number: 20100016361Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: (I) wherein the variants R and X are defined in the specification.Type: ApplicationFiled: February 18, 2008Publication date: January 21, 2010Inventors: Rene Hersperger, Philipp Janser, Wolfgang Miltz
-
Patent number: 7615562Abstract: A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.Type: GrantFiled: April 8, 2004Date of Patent: November 10, 2009Assignee: Novartis AGInventors: Birgit Bollbuck, Alastair DenholmMritain, Jörg Eder, René Hersperger, Philipp Janser, Lászlo Révész, Achim Schlapbach, Rudolf Wálchi
-
Patent number: 7589091Abstract: Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.Type: GrantFiled: April 8, 2003Date of Patent: September 15, 2009Assignee: Novartis AGInventors: Philipp Janser, Wolfgang Miltz, Ulf Neumann
-
Publication number: 20070155721Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.Type: ApplicationFiled: February 10, 2002Publication date: July 5, 2007Inventors: Rene Hersperger, Philipp Janser, Emil Pfenninger, Hans Wuethrich, Wolfgang Miltz
-
Publication number: 20070043048Abstract: A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.Type: ApplicationFiled: April 8, 2004Publication date: February 22, 2007Inventors: Birgit Bollbuck, Alastair DenholMritain, Laszlo Revesz, Achim Schlapbach, Rudolf Walchli, Jorg Eder, Rene Hersperger, Philipp Janser
-
Publication number: 20060063778Abstract: Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.Type: ApplicationFiled: April 8, 2003Publication date: March 23, 2006Inventors: Philipp Janser, Wolfgang Miltz, Ulf Neumann